TAMOXIFEN 20MG by PHARMAQO LABS
Tamoxifen treatment for a long time has been linked to the development of fatty liver, steatohepatitis, cirrhosis, and rare cases of clinically evident acute liver damage. For women at moderate or high risk, a daily dosage of 20 mg for 5 years is advised. A larger dose or a longer time of usage are not recommended due to a lack of evidence.
Take once a day at a dose of 20 mg. Higher dosages have not been shown to provide any extra advantage in terms of delayed recurrence or better patient survival. Although higher dosages have been used in certain individuals with advanced illness, there is no substantial evidence to support the use of 30-40 mg per day therapy. In failed situations, further courses may be administered during future menstrual cycles, with the dose increased to 20 mg twice day, then 40 mg twice daily.
During a pregnancy, Pre-menopausal patients should be checked for pregnancy before starting therapy.
The first step in preventing breast cancer is to understand the basics.
Women who previously experienced a thrombosis of the deep vein or lung embolus.
- Women who need to take coumarin-type anticoagulants at the same time.
The start of therapy for women with irregular menstruation might happen on any given day. If the first course is unsuccessful, a second treatment with a greater dose level may be started after a 45-day gap (20 mg to 40 mg twice daily).
Menstruation is reduced in a subset of premenopausal women using this product for breast cancer therapy.
Tamoxi therapy has been linked to an increased risk of endometrial alterations such as hyperplasia, polyps, malignancy, and uterine sarcoma (mainly malignant mixed Mullerian tumours).
This product may cause or aggravate angioedema symptoms in people with hereditary angioedema.